HLS TherapeuticsTSX:HLS -2.82%62 FCF Yield % is 19.00 as of Jun. 27, 2026, which is 81% above its 10-year median of 10.48. GuruFocus rates TSX:HLS with a GF Score™ of 62/100 and a GF Value™ of C$4.47 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,005 Drug Manufacturers companies, HLS Therapeutics ranks better than 94.93% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
HLS Therapeutics FCF Yield % Related Terms
HLS Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for HLS Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLS Therapeutics (TSX:HLS) has a FCF Yield % of 19.00 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on HLS Therapeutics and its competitors. This is 81% above median its historical median of 10.48. According to the industry distribution chart, HLS Therapeutics ranks #51 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 5.1%.
Is HLS Therapeutics' FCF Yield % too high?
HLS Therapeutics' current FCF Yield % of 19.00 is 81% above median its 10-year median of 10.48. The Drug Manufacturers industry median FCF Yield % is 0.67. HLS Therapeutics' value of 19.00 is 2735.8% above this industry median. Based on the distribution chart, HLS Therapeutics ranks #51 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #51 out of 1005 companies for FCF Yield %. This places HLS Therapeutics in the top 5% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. HLS Therapeutics' value of 19.00 is 2735.8% above this benchmark. While the company's 10-year median is 10.48 vs. the industry median of 0.67, HLS Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HLS Therapeutics's current FCF Yield % of 19.00 is 2735.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on HLS Therapeutics and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HLS Therapeutics's current FCF Yield % is 19.00, which is 81% above median its own 10-year median of 10.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.47, compared to a current price of C$4.14 — trading 7.4% below its estimated fair value. The current FCF Yield % is 19.00, which is 81% above median its 10-year median of 10.48 and 2735.8% above the Drug Manufacturers industry median of 0.67. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current FCF Yield % is 19.00 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$4.14 is trading 7.4% below its estimated GF Value™ of C$4.47.
GuruFocus considers HLS Therapeutics to be Fairly Valued.
Key valuation signals for TSX:HLS:
FCF Yield %: 19.00 (81% above median its 10-year median of 10.48)
GF Value™: C$4.47 vs. price of C$4.14 (7.4% below fair value)
Industry Position: 2735.8% above the Drug Manufacturers median (#51 of 1005)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
62GF Score
Get the complete analysis for TSX:HLS
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 
